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httpConductance sizing balloon for measurement
of peripheral artery minimal stent area
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Background: Because stent underdeployment occurs frequently, accurate minimal stent area (MSA) measurement during
postdilatation is necessary. This study investigated the accuracy and repeatability for MSA determination using a novel
conductance balloon (CB) catheter for peripheral vessels.
Methods: The CB catheter is a standard balloon catheter that measures electrical conductance (ratio of current/voltage
drop) in real-time during inﬂation, which directly relates to the balloon cross-sectional area through Ohm’s law. CB
measurements were made in 4- to 10-mm phantoms on the bench, ex vivo in stents fully deployed in diseased human
peripheral arteries, and in vivo in stents fully deployed in peripheral vessels in six swine. CB measurement accuracy and
repeatability were calculated and compared with the known dimension (bench phantoms) or with intravascular ultra-
sound (IVUS) measurement after stent deployment (ex vivo and in vivo).
Results: CBmeasurements were highly accurate (error: 1.8% bench, 5% ex vivo, and 5% in vivo) and repeatable (error: 0.9%
bench, 1.8% ex vivo, and 1.3% in vivo), with virtually no bias (average difference in measurements:L0.05 mm bench CB
vs known phantom diameters, L0.06 mm ex vivo CB vs IVUS, and L0.11 mm in vivo CB vs IVUS).
Conclusions: The CB sizing capability can be integrated within a standard balloon catheter (two-in-one function) to
provide accurate, real-time assessment of MSA to ensure full stent apposition rather than the use of pressure as a surrogate
for size. (J Vasc Surg 2014;60:759-66.)
Clinical Relevance: Clinically, stent underdeployment is likely given that the expected balloon dimension is often not
reached in vivo (ie, pressure/diameter relationships supplied by the manufacturer are inaccurate in vivo). The conduc-
tance balloon device described here serves as a standard postdilatation balloon with additional real-time, accurate,
dimensional feedback. Balloon usage could eliminate the need for multiple inﬂations and potentially help with compli-
cations related to balloon underinﬂation and stent recoil, including in-stent restenosis, stent thrombosis, and revascu-
larization. The future use of the technology could expand beyond peripheral postdilatation to other balloon applications,
including coronary postdilatation, drug-eluting, cutting, cryoplasty, and valvuloplasty balloons.the Departments of Biomedical Engineering,a Surgery,b and Cardio-
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://dx.doi.org/10.1016/j.jvs.2013.06.095Stenting during percutaneous arterial intervention has
become the standard care for patients with symptomatic
peripheral artery disease.1,2 Stent underdeployment,
deﬁned as failure to have full strut apposition, occurs in
40% of percutaneous peripheral interventions.3,4 There
are even higher reported rates (70%-85%) during percuta-
neous coronary intervention when a more comprehensive
deﬁnition of underdeployment, deﬁned as expansion <90%
of the expected minimal stent diameter or failure to have
full strut apposition with <80% to 90% of the expected
minimal stent area (MSA), is used.5-8 The inability to
achieve adequate deployment with full stent apposition
impacts in-stent restenosis rates, in-stent thrombosis
formation, and target vessel revascularization rates.3,9,10
The reasons for stent underdeployment have been
rigorously evaluated in coronary interventions but to
a much lesser extent in peripheral vessels. Studies have
shown the major culprit is related to balloon underexpan-
sion and device recoil related to plaque and the vessel
wall or the stent metal.11 On the other hand, underdeploy-
ment occurs regardless of stent type (both bare-metal and
drug-eluting stents), stent dimension, manufacturer,
deployment location in the vasculature, percentage of
stenosis, and lesion length.7,8,12,13
Because stent underdeployment is well documented,
balloon postdilatation is often used to achieve appropriate759
Fig 1. a, An example of a conductance balloon (CB) catheter
shows the balloon at the distal end and the injection port and
electrode connector at the proximal end. b, This speciﬁc catheter
contains a 5-mm-diameter, 24-mm-length balloon with electrode
spacing of 4, 1, and 4 mm between consecutive electrodes inside
the balloon.
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nary vessels. Even when postdilatation is used with intravas-
cular ultrasound (IVUS) guidance, a large percentage of
stents still remain underdeployed.14 This is not unex-
pected, however, because postdilatation balloons rely on
ex vivo-derived manufacturer pressure compliance charts
that do not accurately reﬂect the in vivo balloon pres-
sure/diameter relationship.11 Therefore, an integrated
balloon-sizing technology may be useful to aid in accurate
postdilatation sizing for the achievement of proper MSA
and stent apposition in peripheral arteries. Here, a conduc-
tance balloon (CB) catheter is validated that provides real-
time, quantitative, accurate, and repeatable conductance
measurements for MSA sizing on the bench, ex vivo taken
from diseased human peripheral artery specimens, and
in vivo in the peripheral arteries in swine.
METHODS
The CB catheter (Fig 1) is a standard balloon catheter
with a ﬂuid port for inﬂation and an opening for wire
exchange. The CB catheter contains four radiopaque elec-
trically conducting electrodes inside the balloon. The outer
two electrodes serve as the typical angiographic markers on
the edges of the balloon, whereas the inner two electrodes
mark the location of the sizing measurement inside the
balloon. The spacing between the outer electrodes was
generally 20 mm with 1- to 2-mm inner electrode spacing.
The CB catheters tested had balloon diameters of 4 to
10 mm, balloon lengths of 24 to 100 mm, and catheter
lengths of 80 to 150 cm. The balloon material was madeof a noncompliant or semicompliant nylon or urethane
material. The four distal electrodes inside the balloon
were connected to a proximal electrode section that was
connected to a computer console by a connector cable. A
small amount of alternating current was injected through
the outer electrodes at the distal end of the balloon, while
the real-time conductance measurements for sizing were
made across the inner two distal electrodes and displayed
on the console screen. A detailed description of the physical
laws that govern the CB operation is shown in the
Appendix.
Bench validation. The accuracy and repeatability of
CB balloon sizing measurements were tested on the bench.
All CB catheters were individually calibrated in variously
sized phantoms of uniform diameter using a 75%/25%
mixture of saline and contrast (ie, 75% of 0.9% NaCl solu-
tion; Baxter Healthcare, Deerﬁeld, Ill; and 25% of Omnipa-
que contrast, 350 mg/mL; GE Healthcare, Waukesha,
Wisc).
After calibration, each CB catheter was randomly and
repeatedly placed in another set of uniform phantoms, the
conductance was recorded, and the cross-sectional area
(CSA)/diameter was calculated according to Equations 1
and 2 (Appendix). Measurement accuracy was determined
as the difference between the CB catheter and the true
phantom measurement, and repeatability was determined
as the difference between two randomized repeat CB cath-
etermeasurements. The true size of the phantomswas deter-
mined using a set of M1-M2 ﬁxed gauges (Meyer Gauge
Company Inc, South Windsor, Conn).
An identity plot was created for the accuracy (CB cath-
eter vs true) and repeatability (CB catheter measurement 1
vs 2) data. A Bland-Altman analysis was used to assess the
CB catheter measurements compared with the actual
dimension.15 The average, standard deviation, and root
mean square (RMS) error were calculated for the accuracy
and repeatability measurements.
Ex vivo human validation. CB catheter measure-
ments were made ex vivo in four diseased human common
and superﬁcial femoral arteries with nonuniform, calciﬁed
lumen geometries. The specimens were taken from two
male patients with severe peripheral arterial disease and
accompanying ulcerations on the lower leg and foot that
necessitated an amputation above or below the knee. All
specimens were obtained with permission and approval of
the local Institutional Review Board at Wishard Hospital
(Indianapolis, Ind).
After the specimen was isolated, access to the vessel
lumen was established and four peripheral stents (Express
or Express LD; Boston Scientiﬁc, Natick, Mass; and
Palmaz Genesis; Cordis, Bridgewater, NJ) were deployed.
The initial sizing assessment made angiographically and
with IVUS (Visions PV 018 Catheter; Volcano Corp,
San Diego, Calif) showed evidence of nonuniform stent
expansion requiring and thus leading to subsequent
postdilatation.
The CB catheter was advanced, and at least four
repeat measurements were made in each stent. Sizing
Fig 2. Bench accuracy for conductance balloon (CB) catheter
sizing is shown in phantoms with diameters of 4 to 10 mm. The
plots show (a) the identity relationship between the balloon
measurement and the true dimension, with the solid black line as
the identity line, and the (b) Bland-Altman analysis. SD, Standard
deviation.
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tions 1 and 2 (Appendix). Subsequent to CB measure-
ments, an IVUS measurement was made for accuracy
validation. CB catheter accuracy was based on a comparison
with IVUS, and repeatability was based on consecutive CB
measurements. A linear regression, Bland-Altman, and
RMS analysis were all completed for the ex vivo data as in
the bench analysis.15
In vivo animal validation. In vivo validation using the
CB catheter was performed in six healthy domestic swine
(58 6 18 kg). Before each procedure, the CB catheter
was calibrated in appropriately sized phantoms for each
balloon in a water bath heated to body temperature(w37C). Animals were sedated using an intramuscular
injection of TKX (4.4 mg/kg), consisting of Telazol
(50 mg/mL; Zoetis, Florham Park, NJ), ketamine
(25 mg/mL), and xylazine (25 mg/mL), and maintained
on a stable anesthetic plane through intubation and venti-
lation with 100% oxygen and 1% to 2% isoﬂurane. A sheath
was placed for access to the carotid or iliac arteries.
An initial sizing assessment was made for each vessel
(carotid or iliac) using IVUS (Visions PV 018 Catheter).
This sizing assessment was used to select a stent with
a dimension at or slightly greater than the measured
IVUS assessment and deployed according to the manufac-
turer speciﬁcations (Omnilink; Abbott, Abbott Park, Ill;
Boston Scientiﬁc Express and Express LD; and Visi-Pro;
ev3 Endovascular Inc, Plymouth, Minn). After deploy-
ment, an IVUS measurement was made, followed by four
repeat CB catheter sizing measurements (ie, complete
inﬂations, followed by deﬂations). On the basis of standard
interventional practice, the CB catheter measurements
were made after end inﬂation #10 seconds in the carotid
artery and #20 seconds in the iliac artery. The CB catheter
was removed from the vessel, and the IVUS catheter was
placed inside the stent to make the gold standard measure-
ment of the stent size.
Similar to the ex vivo experiments, the accuracy of the
CB catheter measurements (Equations 1 and 2 in the
Appendix) was determined relative to IVUS measurement
after stent deployment. Consecutive CB catheter measure-
ments were used to make paired in vivo repeatability
measurements for each stent. A least squares ﬁt, Bland-
Altman, and RMS analysis were used for the in vivo anal-
ysis, similar to the bench and ex vivo analyses.15
The animal procedures, including euthanasia at the end
of the study, were completed with the approval of the Indi-
ana UniversityePurdue University Indianapolis Institu-
tional Animal Care Use Committee and followed the
recommendations from the Animal Welfare Act, Institute
of Laboratory Animal Research guidelines, and the Public
Health Service policy.
RESULTS
The mean difference between the CB catheter diam-
eter measurements and the true diameter on the bench
was 0.05 6 0.11 mm with an RMS error of 1.8% (accu-
racy, Fig 2, a and b) and a relationship between the
measured and true dimension of y ¼ 0.99x; R2 ¼ 1 (y ¼
CB catheter-measured diameter and x ¼ true diameter;
Fig 2, a). For the repeatability analysis, the mean difference
between repeat measurements was 0.01 6 0.06 mm, with
an RMS error of 0.9% (repeatability, Fig 3, a and b) and
a repeatability relationship of y ¼ 1.0x; R2 ¼ 1 (y ¼ CB
diameter measurement 2 and x ¼ CB diameter measure-
ment 1; Fig 3, a).
For each CB measurement, the system displayed the
real-time temporal change in conductance during inﬂation
(Fig 4, a), which was conﬁrmed with ﬂuoroscopy for the
ex vivo and in vivo measurements (Fig 4, b). The outer
marker electrodes provided visual conﬁrmation for the
Fig 3. Bench repeatability for conductance balloon (CB) catheter
sizing is shown in phantoms with diameters of 4 to 10 mm. The
plots show (a) the identity relationship between repeat measures,
with the solid black line as the identity line, and (b) the Bland-
Altman analysis. SD, Standard deviation.
Fig 4. a, An example is shown of the temporal course of the
conductance balloon (CB) catheter diameter/conductance mea-
surement during inﬂation and deﬂation. b, A cine image shows
a CB catheter during dilatation in vivo in an iliac stent in swine.
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were positioned and visualized in the desired location in
the stent, and the balloon contour was visible during the
inﬂation with the saline/contrast mixture (Fig 4, b).
The ex vivo CB catheter accuracy vs the IVUS
measurement was 0.06 6 0.30 mm, with 5.2% RMS
error (open circles in Fig 5, a and b) and CB catheter
repeatability was 0.01 6 0.10 mm with 1.8% RMS error
(open circles in Fig 6, a and b). The ex vivo accuracy rela-
tionship was y ¼ 0.98x; R2 ¼ 0.97 (where y ¼ CB catheter-
measured diameter and x ¼ IVUS-measured diameter;
Fig 5, a), whereas the ex vivo repeatability relationship
was y ¼ 1.0x; R2 ¼ 1.0 (where y ¼ CB catheter measure-
ment 2 and x ¼ CB catheter measurement 1, Fig 6, a).
In terms of in vivo accuracy (solid squares in Fig 5,
a and b), the CB catheter and IVUS measurements had
a mean difference of e0.11 6 0.35 mm, an RMS errorof 4.9%, and a linear accuracy relationship of y ¼ 0.98x;
R2 ¼ 0.98 (where y ¼ CB catheter-measured diameter
and x ¼ IVUS-measured diameter, Fig 5, a). For in vivo
repeat measurements (solid squares in Fig 6, a and b),
the CB catheter had a mean difference of 0.02 6
0.08 mm, an RMS error of 1.3%, and a linear repeatability
relationship of y ¼ 1.0x; R2 ¼ 1 (where y ¼ CB catheter
measurement 2 and x ¼ CB catheter measurement 1,
Fig 6, a). Before in vivo CB measurements, stents were
underdeployed to 87% 6 7% of the nominal value, despite
inﬂation, according to the manufacturer’s speciﬁcations
(manufacturer-predicted diameter: 7.99 6 2.01 mm vs
actual IVUS diameter: 6.98 6 2.04 mm for in vivo stents).
Fig 5. In vivo swine (solid squares) and ex vivo human (open
circles) conductance balloon (CB) accuracy is shown. a, The
identity relationship between the CB measurement and the intra-
vascular ultrasound (IVUS) dimension, with the solid black line as
the identity line. b, The Bland-Altman analysis shows the mean 6
two standard deviation (SD) lines for the in vivo analysis only.
Fig 6. In vivo swine (solid squares) and ex vivo human (open
circles) conductance balloon (CB) repeatability is shown. a, The
identity relationship between repeat measures, with the solid black
line as the identity line. b, The Bland-Altman analysis shows the
mean 6 two standard deviation (SD) lines for the in vivo analysis
only.
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The CB catheter system provided highly accurate and
reproducible MSA sizing measurements. There was excel-
lent agreement of the CB catheter measurements with
the true lumen dimension on the bench (w2%), ex vivo
(w5%), and in vivo (w5%), excellent repeatability (#2%
for bench, ex vivo, and in vivo), and a nearly perfect linear
relationship (R2 ¼ 1) for each accuracy and repeatability
analysis (Figs 2-6).
The reason for the high CB catheter accuracy and
repeatability was due to the underlying fundamental phys-
ical basis for the technology (Ohm’s law, Equation 1 in
the Appendix) and the insulative nature of the balloon envi-
ronment compared with inaccurate bench-derived manu-
facturer pressure/diameter relationships.11 Because thedistal electrodes are effectively insulated by the balloon
and no current is lost to the surrounding environment (ie,
the balloon acts like a phantom), the Ohm’s law relationship
provides a direct relationship between CSA and measured
conductance. The conductance measurements directly
relate to the CSA of the balloon at the measurement elec-
trodes and do not require a cylindrical balloon assumption
for accurate results (ie, conductance measures CSA directly,
not diameter directly).
This was evidenced by the fact that virtually no differ-
ence in accuracy (w5%) or repeatability (1.5%-1.8%)
existed between normal in vivo swine vessels with circular
cross-sections and the ex vivo diseased human artery spec-
imens with nonuniform geometries. The CB catheter
showed highly accurate sizing across various diameters
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arteries), stent types, and balloon dimensions. Thus, based
on Ohm’s law and the insulative nature of the balloon envi-
ronment, the CB catheter gives accurate and repeatable
sizing results no matter the vessel or stent size, location,
or disease state.
CB catheter accuracy vs the IVUS measurement in vivo
was excellent, with an average (0.11 mm) and standard
deviation (0.35 mm) that was appropriate given the
full-millimeter step resolution that exists for peripheral
stents. The ex vivo and in vivo accuracy (w5%) was small
but was larger than the bench accuracy (w2%). This error
was unlikely due to recoil, because the accuracy differences
between the CB catheter and IVUS measurements were
both positive and negative, with the average bias being
negative, which means CB catheter measurements are
smaller than IVUS measurements and thus cannot be due
to recoil.
However, the slightly larger ex vivo and in vivo error
may be due to other factors, including the inherent error
introduced by the subjective IVUS measurements that is
not present with the bench studies. This study used
a 75/25 mixture ratio of saline and contrast; however,
different mixture ratios can be used to produce the same
precise sizing results if the unique mixture ratio and ﬂuid
conductivity is known and included in the system.
No accurate method currently exists for real-time
quantitative MSA determination during peripheral inter-
ventions. Angiographic assessment (with marked wires/
catheters) and pressure surrogates during balloon expan-
sion provide inaccurate cross-sectional estimates for device
dimension and, thus, may require multiple postdilatations
and IVUS conﬁrmations to achieve the desired MSA.14
Pressure/volume relationships have been used for sizing
in peripheral balloon catheters (eg, Metricath, Neovasc,
Richmond, BC, Canada), but these systems have limited
accuracy because they provide an average balloon size
rather than a precise, focal sizing measurement, as with
the CB catheter.16
Other studies have placed IVUS or optical coherence
tomography transducers inside balloons.17,18 With IVUS
or optical coherence tomography inside a balloon, the
MSA during inﬂation requires user interpretation (ie, not
real-time sizing measurements) and requires the catheter
to increase in size to accommodate the transducer and
the balloon, which is a practical limitation, especially for
other balloon applications such as coronary postdilatation.
However, the CB catheter provides real-time, objective
sizing that can be made to current standard peripheral or
coronary catheter sizes.
The CB catheter can be used as a standard balloon
catheter that provides an additional highly accurate and
reproducible measurement during inﬂation, which allows
the interventionalist to adjust the degree of expansion in
real-time (not possible with standard balloons), eliminates
the need for gradual dilatation(s), reduces X-ray exposure,
and may eliminate the need for additional IVUS evalua-
tion. The CB can also be used to avoid possible barotraumato the vessel intima from hyperinﬂation or prolonged
balloon inﬂation. The use of the CB catheter allows for
the desired MSA to be achieved without overexpansion,
which is important for current stents and clinical trials
involving bioresorbable scaffolds, which are more fragile
than metal stents and have strict restrictions related to
overexpansion.19,20
The CB catheter can also aid in the treatment of bifur-
cation lesions to ensure that the bifurcation dimensions
(each of the three branches) obey design laws in addition
to stent apposition and MSA.21 Chronic total occlusions
can also be treated more adequately using the CB catheter
because these lesions are the most difﬁcult in which to
achieve appropriate postdilatation and would beneﬁt
greatly from real-time feedback about balloon dimension,
which allows the physician to adjust inﬂation instanta-
neously or deliver another therapy. The CB catheter can
be easily extended for other applications, including sizing
for stent delivery balloons, drug-eluting balloons, cutting
balloons, cryoplasty, valvuloplasty, and coronary postdilata-
tion.22-25
No adverse events were seen during in vivo device
usage, and no long-term safety concerns are expected
due to the small alternating current and the insulative
nature of the balloon. Obviously, the next logical step is
for future studies for CB safety and efﬁcacy in vivo in
diseased human arteries.
In general, interventionalists place the center of the
balloon at the center of the underdeployed stent region.
Thus, placing the sensors at the center of the balloon and
making a single measurement are appropriate in many
cases. The current spacing of the inner measurement
sensors was 1 to 2 mm, which implies that the balloon
CSA measurements are averaged across an effective length
along the lesion of 1 to 2 mm, which is adequate resolution
for focal lesions. In some instances, however, intervention-
alists may only use the balloon edge for dilatation, in which
case, a measurement in the balloon center will not accu-
rately reﬂect the dimension at the region of interest on
the balloon edge if the balloon does not expand uniformly.
In the case of very long lesions, where size of balloon
expansion is needed along the length of the lesion, the
CB catheter can be used with multiple sensors for simulta-
neous measurements along the length of the balloon to
create a real-time measurement proﬁle of the balloon
dimension. This is feasible because sensors can be placed
off center and still maintain high calibration accuracy
(data not shown).
The CB catheter achieves accurateMSA and stent appo-
sition by addressing the two known factors that affect
deployment: balloon underexpansion and stent recoil due
to the device or the vessel, or both.11 Balloon underexpan-
sion is addressed with use of the CB catheter due to
the accurate, real-time sizing accomplished through
conductance measurements during inﬂation that does not
depend on ex vivo-derived pressure compliance tables.7,8,11
Thus, whenballoon underexpansion occurs, theCB catheter
provides instantaneous feedback to the physician that more
JOURNAL OF VASCULAR SURGERY
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what was normally predicted by the manufacturer’s compli-
ance charts. In the case that the balloon is not fully expanded
even at the maximum recommended inﬂation pressure,
other therapy options, such as a larger balloon, are required.
If the amount of recoil due to the stent itself is known, then
the CB catheter can achieve the desired MSA by expanding
to larger diameters that account for the stent recoil. Hence,
the catheter provides conﬁrmation that stent apposition
occurs in cases of vascular/plaque recoil.
CONCLUSIONS
The CB catheter is a balloon catheter with additional
sizing functionality that is not currently available clinically
(potential two-in-one functions). The CB catheter allows
for clinically accurate, real-time feedback that can deliver
more effective therapy (potentially decrease stent restenosis
and thrombosis) and thus possibly eliminate the need for
multiple sizing and balloon inﬂations.
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Mathematical and theoretical background for conduc-
tance balloon operation
During balloon inﬂation, the voltage, and in turn, the
conductance measurement made inside the balloon can
be used to determine the balloon dimension based on
a physical law (ie Ohm’s Law, Equation 1 below). Ohm’s
Law states that when a current ﬂows through a resistor,
the cross-sectional area (CSA) of the resistor is equal to
the measured conductance (G) across the resistor times
the length of the resistor (L) divided by the electrical
conductivity of the resistor medium (s), namely:
ð1Þ CSA ¼ GL
s
In the case of the conductance balloon (CB) catheter,
the ﬂuid inside the balloon (a saline and contrast mixture)
is the “resistor medium.” G is measured across the inner28. Kassab GS, Lontis ER, Hørlyck A, Gregersen H. Novel method for
measurement of medium size arterial lumen area with an impedance
catheter: in vivo validation. Am J Physiol Heart Circ Physiol 2005;288:
H2014-20.
29. Kassab GS, Lontis ER, Gregersen H. Measurement of coronary lumen
area using an impedance catheter: ﬁnite element model and in vitro
validation. Ann Biomed Eng 2004;32:1642-53.
Submitted Mar 21, 2013; accepted Jun 29, 2013.electrodes, L is the known distance between the inner elec-
trodes, and s is the known electrical conductivity inherent
to the saline/contrast medium inside the balloon. Because
all of the variables on the right side of Equation 1 are
known or are measured during inﬂation, the balloon CSA
(Equation 1) and effective diameter (D) are directly related
to changes in G as follows:
ð2Þ D ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
4GL
ps
r
The s of the ﬂuid medium inside the balloon is deter-
mined before the procedure from calibration. Calibration
measures G inside the CB catheter in various phantoms
of known CSA in an appropriate size range for each balloon
(eg, a 6-mm-diameter CB catheter was calibrated in phan-
toms from 4 to 6 mm). The slope of the G vs CSA/L rela-
tionship is the s for the mixture of saline and contrast used
to inﬂate the balloon.26-29
